CMPK1

UMP-CMP kinase · P30085 · CMPK1 on Sugi Atlas →

468 patent compounds predicted against CMPK1, 326 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Crenolanib (SCHEMBL2730601)	1.00	1/20
Crenolanib (SCHEMBL29350134)	1.00	1/20
Crenolanib (SCHEMBL29352568)	1.00	1/20
Crenolanib (SCHEMBL30002138)	1.00	1/20
SCHEMBL22567082	0.86	1/20
SCHEMBL5662568	0.85	1/20
Crenolanib (SCHEMBL4681285)	0.85	1/20
Crenolanib (SCHEMBL29352554)	0.85	1/20
Crenolanib (SCHEMBL29361948)	0.85	1/20
SCHEMBL27030604	0.85	1/20
SCHEMBL30775111	0.85	1/20
SCHEMBL23026363	0.82	1/20
SCHEMBL3191766	0.80	1/20
SCHEMBL27030775	0.80	1/20
SCHEMBL30441378	0.80	1/20
SCHEMBL3180117	0.79	1/20
SCHEMBL3189249	0.78	1/20
SCHEMBL3190082	0.78	1/20
SCHEMBL3190135	0.78	1/20
SCHEMBL3182258	0.76	1/20

Clinical trials — most relevant to CMPK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions	PHASE4	UNKNOWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Metformin and Simvastatin Use in Bladder Cancer	PHASE2	UNKNOWN
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV	PHASE1/PHASE2	COMPLETED
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.	PHASE2	COMPLETED
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial	PHASE1/PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction	PHASE2	UNKNOWN
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States	nan	COMPLETED
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors	nan	UNKNOWN
Effect of Metformin on Chronic Pain After Thoracic Surgery in Diabetic Patients	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CMPK1 binder may also engage these)

Protein	Name	Similarity
Q29561	—	1.000	Q29561 →
Q4KM73	—	1.000	Q4KM73 →
Q9DBP5	—	1.000	Q9DBP5 →
Q7ZWE9	—	1.000	Q7ZWE9 →
Q2KIW9	—	1.000	Q2KIW9 →
Q5ZKE7	—	0.996	Q5ZKE7 →
Q7ZX23	—	0.995	Q7ZX23 →
Q28H12	—	0.994	Q28H12 →
Q20230	—	0.994	Q20230 →
O17622	—	0.990	O17622 →
P15700	—	0.989	P15700 →
O59771	—	0.989	O59771 →
P20425	—	0.986	P20425 →
Q8VY84	—	0.984	Q8VY84 →
P25824	—	0.983	P25824 →
G4V9S0	—	0.983	G4V9S0 →
O59845	—	0.978	O59845 →
A5E598	—	0.977	A5E598 →
Q4WJ21	—	0.974	Q4WJ21 →
Q9U915	—	0.974	Q9U915 →
Q5A4Q1	—	0.974	Q5A4Q1 →
Q0C7Y1	—	0.974	Q0C7Y1 →
B3NQ53	—	0.974	B3NQ53 →
P29410	—	0.974	P29410 →
B4QBH8	—	0.974	B4QBH8 →
B4SA64	—	0.973	B4SA64 →
Q3ASD2	—	0.973	Q3ASD2 →
A1CQR5	—	0.973	A1CQR5 →
Q290A8	—	0.973	Q290A8 →
Q7MW54	—	0.973	Q7MW54 →